Jurgen Scheller

Heine, NW 40225, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 125 publications

Joined Signatures of Erythropoietin and Interleukin-6 Signaling by Synthetic Heterodimeric gp130:Epo Receptor Complexes.

Joined Signatures of Erythropoietin and Interleukin-6 Signaling by Synthetic Heterodimeric gp130:Epo Receptor Complexes.

Journal: ACS synthetic biology

Published: January 13, 2026

Receptor engineering constitutes feedback control and robustness of IL-23R signaling and highlights importance of intracellular cytokine receptor signaling motifs.

Receptor engineering constitutes feedback control and robustness of IL-23R signaling and highlights importance of intracellular cytokine receptor signaling motifs.

Journal: Cell communication and signaling : CCS

Published: October 18, 2025

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering.

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering.

Journal: mAbs

Published: September 25, 2025

SIRT4 positively regulates autophagy via ULK1, but independently of HDAC6 and OPA1.

SIRT4 positively regulates autophagy via ULK1, but independently of HDAC6 and OPA1.

Journal: FEBS open bio

Published: May 06, 2025

Targeting the major pro-inflammatory interleukin-6-type cytokine receptor gp130 by antagonistic single domain antibodies.

Targeting the major pro-inflammatory interleukin-6-type cytokine receptor gp130 by antagonistic single domain antibodies.

Journal: Frontiers in immunology

Published: April 16, 2025

Taming interleukin-12: Engineering of bispecific antibody-based IL-12 mimetics with biased agonism capacities.

Taming interleukin-12: Engineering of bispecific antibody-based IL-12 mimetics with biased agonism capacities.

Journal: Protein science : a publication of the Protein Society

Published: October 22, 2024

An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling.

An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling.

Journal: The Journal of biological chemistry

Published: September 23, 2024

Increased Expression of the Neuropeptides PACAP/VIP in the Brain of Mice with CNS Targeted Production of IL-6 Is Mediated in Part by Trans-Signalling.

Increased Expression of the Neuropeptides PACAP/VIP in the Brain of Mice with CNS Targeted Production of IL-6 Is Mediated in Part by Trans-Signalling.

Journal: International journal of molecular sciences

Published: August 13, 2024

Synthetic trimeric interleukin-6 receptor complexes with a STAT3 phosphorylation dominated activation profile.

Synthetic trimeric interleukin-6 receptor complexes with a STAT3 phosphorylation dominated activation profile.

Journal: Cytokine

Published: August 07, 2024

A refined TTC assay precisely detects cardiac injury and cellular viability in the infarcted mouse heart.

A refined TTC assay precisely detects cardiac injury and cellular viability in the infarcted mouse heart.

Journal: Scientific reports

Published: June 13, 2024

Interleukin-11 receptor is an alternative α-receptor for interleukin-6 and the chimeric cytokine IC7.

Interleukin-11 receptor is an alternative α-receptor for interleukin-6 and the chimeric cytokine IC7.

Journal: The FEBS journal

Published: February 29, 2024

Intratumoral Delivery of Genetically Engineered Anti-IL-6 Trans-signaling Therapeutics.

Intratumoral Delivery of Genetically Engineered Anti-IL-6 Trans-signaling Therapeutics.

Journal: Molecular biotechnology

Published: February 20, 2024

Showing 1-12 of 125

Last Updated: 09/26/2026